Welcome to our dedicated page for HRC news (Ticker: HRC), a resource for investors and traders seeking the latest updates and insights on HRC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HRC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HRC's position in the market.
Hillrom (HRC) announced it will host its fiscal third-quarter 2021 earnings conference call and webcast on July 30, 2021, starting at 7:30 a.m. (CT). Investors can participate by dialing (844) 654-5620 domestically or (647) 253-8654 internationally. A live webcast will be available on Hillrom's website, along with a supplementary presentation. The call will be archived online, and replays can be accessed for seven days post-call. Hillrom continues to enhance patient outcomes globally through its advanced medical technologies.
Hillrom (NYSE: HRC) will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, with a fireside chat led by Barbara Bodem, SVP & Chief Financial Officer, at 10:00 a.m. Eastern Time. The presentation can be accessed via a live webcast on www.hillrom.com, and a recorded replay will be available for 90 days post-event. Hillrom is a leader in medical technology, improving patient outcomes through innovative solutions that enhance care delivery.
On May 4, 2021, Hillrom (HRC) announced a dividend of $0.24 per share for the third quarter of fiscal 2021. This dividend is payable on June 30, 2021, to shareholders recorded as of June 18, 2021. The indicated annual dividend rate is $0.96 per share. Hillrom is a global leader in medical technology, enhancing patient outcomes through innovations that improve diagnosis, treatment, and recovery.
Hillrom (NYSE: HRC) announced strong fiscal Q2 2021 results, with GAAP earnings of $1.30 per diluted share, up from $0.70 year-over-year. Adjusted earnings rose 35% to $1.73, exceeding guidance. Revenue was $762 million, a 5% increase, driven by growth across all segments, particularly in critical care products. The company raised its FY2021 revenue guidance to 1-3% growth, and adjusted earnings expected between $6.00-$6.10 per share. However, Q3 guidance indicates a revenue decline of 7-9% due to challenging comparisons.
On April 28, 2021, Hillrom (NYSE: HRC) announced its participation in the BofA Securities 2021 Virtual Health Care Conference scheduled for May 11, 2021. CEO John Groetelaars will engage in a fireside chat at 9:30 a.m. Eastern Time, followed by virtual one-on-one meetings. Investors can access the live webcast at hillrom.com, with a recorded replay available for 90 days post-event. Hillrom focuses on enhancing patient and caregiver outcomes through connected care solutions, impacting over 7 million patients daily.
Hillrom (NYSE: HRC) announced the launch of its innovative Welch Allyn® PanOptic™ Plus Ophthalmoscope and MacroView® Plus Otoscope, enhancing physical assessment tools. These devices offer significant advancements for patient examinations, featuring a 20-times larger viewing area and digital image capture capabilities. The otoscope includes a unique LumiView speculum ensuring four times brighter assessments. The products are now available in the U.S. and will expand to several international markets later this year. These innovations aim to improve diagnostic accuracy and patient outcomes through routine exams.
On April 10, 2021, Novitas Solutions updated reimbursement rates for CPT codes related to Bardy Diagnostics' extended Holter cardiac monitoring. Hillrom, which intends to acquire BardyDx, indicated a "Company Material Adverse Effect" has occurred due to this decision, leading to unsatisfied closing conditions for the acquisition agreement. Litigation is ongoing with BardyDx, with a trial set for May 5, 2021. Hillrom is committed to long-term shareholder value and will hold a fiscal Q2 2021 earnings call on April 30, 2021.
Hillrom (HRC) will conduct its fiscal second quarter 2021 earnings conference call on April 30, 2021, at 7:30 a.m. CT. Investors can join by calling (844) 654-5620 for domestic or (647) 253-8654 for international access, using confirmation code 1398146. The call will also be available via a webcast on their website, with a recorded replay for 7 days post-call.
Hillrom is a medical technology leader, enhancing patient outcomes through innovative care solutions for over 7 million patients daily, focusing on connected care technologies.
Hillrom (HRC) announced a 9% increase in its quarterly dividend from $0.22 to $0.24 per share. The dividend is payable on March 31, 2021, to shareholders of record by March 22, 2021. The annual dividend rate is $0.96 per share, marking the eleventh consecutive year of dividend increases. CEO John Groetelaars expressed the company's commitment to providing shareholder returns while maintaining financial flexibility for future investments.
Hillrom (NYSE: HRC) will present at KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 23, 2021. CEO John Groetelaars will participate in a fireside chat at 10:00 a.m. ET via webcast, followed by virtual one-on-one meetings. The presentation can be accessed live at www.hillrom.com, and a recorded replay will be available for 90 days post-event. Hillrom is a leading medical technology company, improving patient outcomes through innovative connected care solutions.
